1. Home
  2. TISI vs ACRV Comparison

TISI vs ACRV Comparison

Compare TISI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Team Inc.

TISI

Team Inc.

HOLD

Current Price

$16.34

Market Cap

71.5M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.38

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TISI
ACRV
Founded
1973
2018
Country
United States
United States
Employees
6800
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.5M
82.2M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
TISI
ACRV
Price
$16.34
$1.38
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
12.1K
402.8K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
$896,483,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
5.19
N/A
52 Week Low
$12.34
$1.15
52 Week High
$20.79
$3.56

Technical Indicators

Market Signals
Indicator
TISI
ACRV
Relative Strength Index (RSI) 49.86 30.33
Support Level $13.12 $1.29
Resistance Level $16.62 $2.22
Average True Range (ATR) 0.99 0.10
MACD 0.12 -0.03
Stochastic Oscillator 40.59 1.90

Price Performance

Historical Comparison
TISI
ACRV

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: